Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Debt Repayments (2017 - 2025)

Adma Biologics (ADMA) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $469000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments fell 99.22% year-over-year to $469000.0, compared with a TTM value of $30.9 million through Dec 2025, down 85.85%, and an annual FY2025 reading of $938000.0, down 98.44% over the prior year.
  • Long-Term Debt Repayments was $469000.0 for Q4 2025 at Adma Biologics, up from -$29.5 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $158.6 million in Q4 2023 and bottomed at -$29.5 million in Q3 2025.
  • Average Long-Term Debt Repayments over 4 years is $57.9 million, with a median of $60.0 million recorded in 2024.
  • The sharpest move saw Long-Term Debt Repayments plummeted 62.17% in 2024, then tumbled 99.22% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $100.0 million in 2022, then soared by 58.58% to $158.6 million in 2023, then plummeted by 62.17% to $60.0 million in 2024, then crashed by 99.22% to $469000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for ADMA at $469000.0 in Q4 2025, -$29.5 million in Q3 2025, and $60.0 million in Q4 2024.